QNCX

Quince Therapeutics (QNCX)

Quince Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:QNCX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/28	06 : 01	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:QNCX	Quince Therapeutics Inc
2024/12/27	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:QNCX	Quince Therapeutics Inc
2024/12/19	06 : 03	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:QNCX	Quince Therapeutics Inc
2024/11/14	20 : 55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QNCX	Quince Therapeutics Inc
2024/11/14	11 : 17	Edgar (US Regulatory)	Form SC 13D - General Statement of Acquisition of Beneficial Ownership	NASDAQ:QNCX	Quince Therapeutics Inc
2024/11/14	07 : 09	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:QNCX	Quince Therapeutics Inc
2024/11/14	06 : 05	Business Wire	Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results	NASDAQ:QNCX	Quince Therapeutics Inc
2024/11/13	06 : 05	Business Wire	Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research	NASDAQ:QNCX	Quince Therapeutics Inc
2024/11/12	06 : 05	Business Wire	Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting	NASDAQ:QNCX	Quince Therapeutics Inc
2024/10/15	05 : 05	Business Wire	Quince Therapeutics to Participate at Upcoming Investor Conferences	NASDAQ:QNCX	Quince Therapeutics Inc
2024/09/04	05 : 05	Business Wire	Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference	NASDAQ:QNCX	Quince Therapeutics Inc
2024/08/22	07 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:QNCX	Quince Therapeutics Inc
2024/08/15	20 : 00	Business Wire	Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)	NASDAQ:QNCX	Quince Therapeutics Inc
2024/08/14	05 : 11	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:QNCX	Quince Therapeutics Inc
2024/08/14	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QNCX	Quince Therapeutics Inc
2024/08/14	05 : 05	Business Wire	Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results	NASDAQ:QNCX	Quince Therapeutics Inc
2024/06/25	20 : 00	Business Wire	Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia	NASDAQ:QNCX	Quince Therapeutics Inc
2024/06/08	10 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:QNCX	Quince Therapeutics Inc
2024/06/08	10 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:QNCX	Quince Therapeutics Inc
2024/06/08	09 : 59	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:QNCX	Quince Therapeutics Inc
2024/06/07	06 : 17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QNCX	Quince Therapeutics Inc
2024/06/06	03 : 37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:QNCX	Quince Therapeutics Inc
2024/06/03	20 : 00	Business Wire	Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System	NASDAQ:QNCX	Quince Therapeutics Inc
2024/05/13	20 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:QNCX	Quince Therapeutics Inc
2024/05/13	20 : 00	Business Wire	Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	NASDAQ:QNCX	Quince Therapeutics Inc
2024/05/07	05 : 05	Business Wire	Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference	NASDAQ:QNCX	Quince Therapeutics Inc
2024/04/01	20 : 00	Business Wire	Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results	NASDAQ:QNCX	Quince Therapeutics Inc
2024/02/22	21 : 00	Business Wire	Quince Therapeutics Launches Scientific Advisory Board	NASDAQ:QNCX	Quince Therapeutics Inc
2024/02/16	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QNCX	Quince Therapeutics Inc
2024/02/15	21 : 00	Business Wire	Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors	NASDAQ:QNCX	Quince Therapeutics Inc